Hydroxychloroquine is a novel therapeutic approach for rosacea.

Rosacea is a chronic inflammatory disease in face. Hydroxychloroquine (HCQ), an anti-malaria drug, was reported to have anti-inflammation activities. However, the role of HCQ on rosacea remains unclear. In this study, we revealed the potential molecular mechanism by which HCQ improved rosacea in rosacea-like mice and mast cells (MCs). Moreover, the effects of HCQ treatment for rosacea patients were investigated. In this study, we found HCQ ameliorated the rosacea-like phenotype and MCs infiltration. The elevated pro-inflammatory factors and mast cell protease were significantly inhibited by HCQ treatment in rosacea-like mice. In vitro, HCQ suppresses LL37-induced MCs activation in vitro, including the release of inflammatory factors, chemotaxis, degranulation and calcium influx. Moreover, HCQ attenuated LL37-mediated MCs activation partly via inhibiting KCa3.1-mediated calcium signaling. Thus, these evidences suggest HCQ ameliorated rosacea-like dermatitis may be by regulating immune response of MCs. Finally, the 8-week HCQ treatment exerted satisfactory therapeutic effects on erythema and inflammatory lesions of rosacea patients, indicating that it is a promising drug for rosacea in clinical treatment. Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Citation

Ji Li, Xin Yuan, Yan Tang, Ben Wang, Zhili Deng, Yingxue Huang, Fangfen Liu, Zhixiang Zhao, Yiya Zhang. Hydroxychloroquine is a novel therapeutic approach for rosacea. International immunopharmacology. 2020 Feb;79:106178

Mesh Tags

Substances

PMID: 31918061

search → result